These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18974132)

  • 1. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.
    Risinger AL; Jackson EM; Polin LA; Helms GL; LeBoeuf DA; Joe PA; Hopper-Borge E; Ludueña RF; Kruh GD; Mooberry SL
    Cancer Res; 2008 Nov; 68(21):8881-8. PubMed ID: 18974132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
    Tinley TL; Randall-Hlubek DA; Leal RM; Jackson EM; Cessac JW; Quada JC; Hemscheidt TK; Mooberry SL
    Cancer Res; 2003 Jun; 63(12):3211-20. PubMed ID: 12810650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taccalonolide Microtubule Stabilizers.
    Yee SS; Du L; Risinger AL
    Prog Chem Org Nat Prod; 2020; 112():183-206. PubMed ID: 33306174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers.
    Li J; Risinger AL; Peng J; Chen Z; Hu L; Mooberry SL
    J Am Chem Soc; 2011 Nov; 133(47):19064-7. PubMed ID: 22040100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taccalonolides: Novel microtubule stabilizers with clinical potential.
    Risinger AL; Mooberry SL
    Cancer Lett; 2010 May; 291(1):14-9. PubMed ID: 19880245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and biological activities of new taccalonolide microtubule stabilizers.
    Peng J; Risinger AL; Fest GA; Jackson EM; Helms G; Polin LA; Mooberry SL
    J Med Chem; 2011 Sep; 54(17):6117-24. PubMed ID: 21800839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.
    Risinger AL; Li J; Bennett MJ; Rohena CC; Peng J; Schriemer DC; Mooberry SL
    Cancer Res; 2013 Nov; 73(22):6780-92. PubMed ID: 24048820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
    Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
    Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taccalonolide microtubule stabilizers.
    Li J; Risinger AL; Mooberry SL
    Bioorg Med Chem; 2014 Sep; 22(18):5091-6. PubMed ID: 24491636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taccalonolides: A Novel Class of Microtubule-Stabilizing Anticancer Agents.
    Chen X; Winstead A; Yu H; Peng J
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation.
    Risinger AL; Riffle SM; Lopus M; Jordan MA; Wilson L; Mooberry SL
    Mol Cancer; 2014 Feb; 13():41. PubMed ID: 24576146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
    Yang CH; Wang C; Ojima I; Horwitz SB
    J Nat Prod; 2018 Mar; 81(3):600-606. PubMed ID: 29517223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJ.
    Risinger AL; Li J; Du L; Benavides R; Robles AJ; Cichewicz RH; Kuhn JG; Mooberry SL
    J Nat Prod; 2017 Feb; 80(2):409-414. PubMed ID: 28112516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.
    Pusztai L
    Ann Oncol; 2007 Dec; 18 Suppl 12():xii15-20. PubMed ID: 18083698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.